Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Washington University School of Medicine Foundation for Anesthesia Education and Research |
---|---|
Information provided by: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00655980 |
In this study, we want to find out if laughing gas (nitrous oxide) leads to a higher rate of cardiac complications after surgery in patients with a specific genetic profile (mutations in the MTHFR gene) and if this risk can be prevented by giving patients vitamin B12 and folate during surgery.
Condition | Intervention |
---|---|
Major Vascular Surgery Coronary Artery Disease |
Drug: Vitamin B12 and folic acid |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Placebo Control, Factorial Assignment |
Official Title: | Pharmacogenetics of Adverse Outcomes After Nitrous Oxide Anesthesia |
Estimated Enrollment: | 500 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Patients homozygous for MTHFR 677 C>T and 1298 A>G + receiving vitamins before and after surgery |
Drug: Vitamin B12 and folic acid
1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
|
2: Placebo Comparator
Patients homozygous for MTHFR 677 C>T and 1298 A>G receiving placebo infusion (plain normal saline 100ml)
|
Drug: Vitamin B12 and folic acid
1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
|
3: Experimental
Patients wildtype for MTHFR 677 C>T and 1298 A>G + receiving vitamin B12 and folic acid before and after surgery |
Drug: Vitamin B12 and folic acid
1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
|
4: Placebo Comparator
Patients wild-type for MTHFR 677 C>T and 1298 A>G + receiving placebo (100 ml NS infusion) |
Drug: Vitamin B12 and folic acid
1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
|
Background and significance: Recent studies have shown that nitrous oxide (N2O) anesthesia may be associated with an increased risk of adverse cardiovascular outcomes. It is well-known that N2O inhibits vitamin B12-dependent enzymes and as a result increases plasma homocysteine concentrations. Homocysteine has been identified as risk factor for cardiovascular disease. Therefore elevations in homocysteine after N2O may be a causative factor in N2O toxicity. In a previous investigation, we found that patients who carry a homozygous mutation in the MTHFR gene develop higher homocysteine levels after N2O anesthesia than non-carriers. These patients might be at higher risk for adverse cardiac outcomes from N2O. Thus, there may be a pharmacogenetic mechanism to account for the adverse cardiac outcomes from N2O. Moreover, prevention of N2O-increased homocysteine concentrations in these high risk patients by perioperative vitamin B12 and folate supplementation might decrease the incidence of adverse cardiac outcomes.
Hypothesis: Patients carrying a homozygous MTHFR 677C>T or 1298 A>C variant allele will have a higher incidence rate of postoperative myocardial ischemia after N2O anesthesia [detected by serial TnI measurements] due to elevated homocysteine levels than normal "wild-type" non-carriers, and that the incidence rate will be reduced if they receive perioperative vitamin B12/folate supplementation.
Primary outcome: Myocardial ischemia in the first 72 hours after surgery
Outcome definition: Peak serum troponin I concentration during the first 3 postoperative days
Secondary outcome: Composite endpoint of 30-day mortality and major cardiac morbidity (non-fatal MI)
Design: Randomized controlled trial. Patients will be randomized to receive vitamin supplementation or placebo before surgery. All patients will receive N2O during surgery. Mendelian randomization of MTHFR genotype.
Intervention: IV vitamin B12 (1 mg) and folate (5 mg) preoperatively
Study setting: Barnes-Jewish-Hospital, St. Louis, MO
Patients: Patients scheduled for major vascular surgery with previously diagnosed coronary artery disease
Statistical Approach: Comparison of two groups: MTHFR homozygous vs. heterozygous/wild-type patients. General linear model will be fit to the data after normalizing transformation (e.g. log troponin).
Anticipated result: Patients carrying a homozygous MTHFR 677C>T or 1298 A>C variant allele will have a 50% increased peak TnI due to elevated homocysteine compared to non-carriers. Secondly, treatment with vitamin B12/folate will prevent the homocysteine increase as well as the increase in peak troponin and myocardial ischemia.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Peter Nagele, MD | 314-362-5129 | nagelep@wustl.edu |
Contact: Teresa Bieg, RN | 314-747-5531 | biegt@WUSTL.EDU |
United States, Missouri | |
Barnes-Jewish Hospital | Recruiting |
St. Louis, Missouri, United States, 63110 |
Principal Investigator: | Peter Nagele, MD | Washington University School of Medicine |
Responsible Party: | Dept of Anesthesiology, Washington University School of Medicine ( Peter Nagele, M.D. ) |
Study ID Numbers: | HSC 07-0592 |
Study First Received: | April 4, 2008 |
Last Updated: | April 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00655980 |
Health Authority: | United States: Institutional Review Board |
Folic Acid Arterial Occlusive Diseases Coronary Disease Heart Diseases Nitrous Oxide Myocardial Ischemia |
Hydroxocobalamin Vascular Diseases Vitamin B 12 Arteriosclerosis Ischemia Coronary Artery Disease |
Vitamin B Complex Hematinics Growth Substances Physiological Effects of Drugs Hematologic Agents Central Nervous System Depressants Anesthetics Pharmacologic Actions Anesthetics, Inhalation Anesthetics, General |
Analgesics, Non-Narcotic Sensory System Agents Vitamins Therapeutic Uses Cardiovascular Diseases Peripheral Nervous System Agents Micronutrients Analgesics Central Nervous System Agents |